These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 12840235

  • 1. Prospective evaluation of early abciximab and primary percutaneous intervention for patients with ST elevation myocardial infarction complicated by cardiogenic shock: results of the REO-SHOCK trial.
    Zeymer U, Tebbe U, Weber M, Vohringer HF, Jaksch R, Bischoff KO, Toepel W, Marsalek P, Horn S, Neuhaus KL, ALKK Study Group.
    J Invasive Cardiol; 2003 Jul; 15(7):385-9. PubMed ID: 12840235
    [Abstract] [Full Text] [Related]

  • 2. Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study.
    Tousek P, Rokyta R, Tesarova J, Pudil R, Belohlavek J, Stasek J, Rohac F, Widimsky P.
    Acute Card Care; 2011 Sep; 13(3):116-22. PubMed ID: 21526919
    [Abstract] [Full Text] [Related]

  • 3. Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention.
    Huang R, Sacks J, Thai H, Goldman S, Morrison DA, Barbiere C, Ohm J.
    Catheter Cardiovasc Interv; 2005 May; 65(1):25-33. PubMed ID: 15800889
    [Abstract] [Full Text] [Related]

  • 4. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
    Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E.
    Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
    [Abstract] [Full Text] [Related]

  • 5. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, Mehran R, Grines CL, Garcia E.
    Circulation; 2004 Sep 21; 110(12):1598-604. PubMed ID: 15353506
    [Abstract] [Full Text] [Related]

  • 6. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
    Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.
    Circulation; 2010 Dec 21; 122(25):2709-17. PubMed ID: 21098442
    [Abstract] [Full Text] [Related]

  • 7. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction.
    Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG.
    Am J Cardiol; 2002 Jan 15; 89(2):132-6. PubMed ID: 11792330
    [Abstract] [Full Text] [Related]

  • 8. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
    Taglieri N, Saia F, Guiducci V, Tondi S, Conrotto F, Marrozzini C, Rocchi G, Biagini E, Reggiani ML, Giacometti P, Piovaccari G, Manari A, Marzocchi A, FATA Trial Investigators.
    Am J Cardiol; 2009 Mar 15; 103(6):785-90. PubMed ID: 19268732
    [Abstract] [Full Text] [Related]

  • 9. Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery.
    Tödt T, Sederholm-Lawesson S, Stenestrand U, Alfredsson J, Janzon M, Swahn E.
    Acute Card Care; 2010 Mar 15; 12(1):10-7. PubMed ID: 20201657
    [Abstract] [Full Text] [Related]

  • 10. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators.
    N Engl J Med; 2002 Mar 28; 346(13):957-66. PubMed ID: 11919304
    [Abstract] [Full Text] [Related]

  • 11. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock.
    Giri S, Mitchel J, Azar RR, Kiernan FJ, Fram DB, McKay RG, Mennett R, Clive J, Hirst JA.
    Am J Cardiol; 2002 Jan 15; 89(2):126-31. PubMed ID: 11792329
    [Abstract] [Full Text] [Related]

  • 12. Comparative early and late outcomes after primary percutaneous coronary intervention in ST-segment elevation and non-ST-segment elevation acute myocardial infarction (from the CADILLAC trial).
    Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, Mehran R, O'Neill WW, Lansky AJ, Griffin JJ, CADILLAC Investigators.
    Am J Cardiol; 2006 Aug 01; 98(3):331-7. PubMed ID: 16860018
    [Abstract] [Full Text] [Related]

  • 13. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
    Pels K, Schröder J, Witzenbichler B, Müller D, Morguet A, Pauschinger M, Schultheiss HP, Arntz HR.
    Eur J Emerg Med; 2008 Dec 01; 15(6):324-9. PubMed ID: 19078834
    [Abstract] [Full Text] [Related]

  • 14. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
    Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.
    Circulation; 2008 Jul 01; 118(1):49-57. PubMed ID: 18559698
    [Abstract] [Full Text] [Related]

  • 15. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
    Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gottwik M, Bonzel T, Senges J, Neuhaus KL, Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).
    Eur Heart J; 2004 Feb 01; 25(4):322-8. PubMed ID: 14984921
    [Abstract] [Full Text] [Related]

  • 16. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
    Rakowski T, Siudak Z, Dziewierz A, Birkemeyer R, Legutko J, Mielecki W, Depukat R, Janzon M, Stefaniak J, Zmudka K, Dubiel JS, Partyka L, Dudek D.
    Am Heart J; 2009 Oct 01; 158(4):569-75. PubMed ID: 19781416
    [Abstract] [Full Text] [Related]

  • 17. Early coronary angioplasty for acute myocardial infarction complicated by cardiogenic shock: have novel therapies led to better results?
    Moreno R, Garcia E, Abeytua M, Soriano J, Acosta J, Perez De Isla L, Lopez De Sa E, Rubio R, Lopez-Sendon J.
    J Invasive Cardiol; 2000 Dec 01; 12(12):597-604. PubMed ID: 11103025
    [Abstract] [Full Text] [Related]

  • 18. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, Neumann FJ, Smith JJ, Topol E, Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators.
    Am Heart J; 2004 Apr 01; 147(4):E16. PubMed ID: 15077099
    [Abstract] [Full Text] [Related]

  • 19. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
    Dangas G, Aymong ED, Mehran R, Tcheng JE, Grines CL, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW, CADILLAC Investigators.
    Am J Cardiol; 2004 Oct 15; 94(8):983-8. PubMed ID: 15476608
    [Abstract] [Full Text] [Related]

  • 20. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P, ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up.
    N Engl J Med; 2001 Jun 21; 344(25):1895-903. PubMed ID: 11419426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.